Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Voloridge Investment Management LLC

Voloridge Investment Management LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 31.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 880,112 shares of the biopharmaceutical company's stock after selling 397,497 shares during the period. Voloridge Investment Management LLC owned about 0.29% of Amicus Therapeutics worth $8,291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vestal Point Capital LP acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $31,557,000. Sovereign s Capital Management LLC bought a new stake in shares of Amicus Therapeutics during the fourth quarter valued at approximately $2,806,000. Virtus Fund Advisers LLC bought a new stake in shares of Amicus Therapeutics during the fourth quarter valued at approximately $29,000. Virtus Investment Advisers Inc. bought a new stake in Amicus Therapeutics during the fourth quarter worth $142,000. Finally, Squarepoint Ops LLC grew its stake in Amicus Therapeutics by 113.4% in the 4th quarter. Squarepoint Ops LLC now owns 1,417,152 shares of the biopharmaceutical company's stock valued at $13,350,000 after purchasing an additional 753,060 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on FOLD shares. Wells Fargo & Company dropped their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. UBS Group increased their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded down $0.08 during mid-day trading on Friday, reaching $6.14. The stock had a trading volume of 592,233 shares, compared to its average volume of 2,874,113. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market cap of $1.89 billion, a P/E ratio of -34.08, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a 1 year low of $5.81 and a 1 year high of $12.65. The business's 50 day moving average price is $6.89 and its 200 day moving average price is $8.61.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.